Unexpected U.S. Growth Throws Cold Water on Markets

The U.S. economy's stronger-than-expected growth has left global financial markets in mixed territory. The U.S. Q3 GDP growth rate announced on the 30th (local time) recorded an annualized 4.3%. This significantly surpasses the market expectation of 3.2% and is even higher than the previous quarter's 3.8%.

France's CAC 40 index closed down 0.2% at 8,104 points that day. Government bond yields rose as the possibility of a January interest rate cut by the Federal Reserve (Fed), which investors had been anticipating, virtually disappeared.

Rate Cut Scenario Shaken

The impact of this growth rate announcement on markets is far from simple. If the economy is growing at this pace, the Fed has less reason to lower interest rates. Markets had expected an additional rate cut at the January 28 Fed meeting, but that scenario has now lost momentum.

In financial markets, expectations have become dominant that a tight monetary policy stance will be maintained for the time being. While this is a burden for stock markets, it acted as a positive factor for gold prices. In fact, gold prices hit record highs, a phenomenon resulting from investors seeking safe-haven assets amid geopolitical tensions between the U.S. and Venezuela.

Novo Nordisk's Game-Changing Card in Obesity Treatment Competition

Meanwhile, interesting news emerged from the pharmaceutical industry. Danish pharmaceutical company Novo Nordisk received FDA approval for an oral version of its obesity treatment drug 'Wegovy.'

The company had a difficult year with its stock price plummeting 47%. At the beginning of the year, it was Europe's largest company by market capitalization, surpassing LVMH, but poor performance and intensifying competition evaporated nearly half its value. The company also struggled to defend its market share as low-cost generic drugs emerged in the U.S. (later banned).

However, the emergence of oral Wegovy shows signs of changing the landscape. Clinical trial results showed weight loss effects similar to the injectable version, with the pill form greatly improving patient convenience. Sales will begin in the U.S. next month, and European approval has also been applied for.

Market reaction was immediate. Novo Nordisk's stock price surged 9% on the Copenhagen stock exchange. Particularly noteworthy is that with competitor Eli Lilly's similar oral product not yet approved, Novo Nordisk has taken the lead once again.

New Phase in Global Obesity Treatment Market

The obesity treatment market has grown explosively in recent years. As GLP-1 class drugs have proven effective not only for weight loss but also for preventing cardiovascular disease, they've become a key battleground in the pharmaceutical industry.

Novo Nordisk and Eli Lilly have formed a duopoly in this market. The focus is now shifting from injectable-centered competition to convenience-of-use competition. If oral products are fully launched, patient accessibility will greatly increase, likely expanding the market size itself.

Future Outlook [AI Analysis]

The U.S. economy's solid growth momentum is likely to slow the Fed's pace of interest rate cuts for the time being. With inflation pressures not completely gone and GDP showing growth in the 4% range, it will be difficult for the central bank to move hastily.

In the obesity treatment market, competition for oral products is expected to intensify. While Novo Nordisk will secure the market preemptively, Eli Lilly is expected to catch up soon. Considering both companies' technological capabilities and production capacity, fierce market share battles are likely to unfold over the coming years.

Gold prices are expected to continue their strength as geopolitical uncertainty and monetary policy tightening intertwine. The preference for safe-haven assets appears unlikely to break in the short term.